- Chief Compliance Officer and VP of Legal Affairs, Arrow Electronics
By 
Adrianne Appel2024-11-15T19:28:00
A pharmaceutical company and its chief executive have agreed to pay $47 million to settle allegations, first brought by whistleblowers, that the company paid kickbacks and filed false claims, the Department of Justice said.
The U.S. Department of Health and Human Services (HHS), which manages Medicare, Medicaid and other federal health programs, takes a hard line against free tests, drugs or offerings provided to patients or doctors, actions which may induce them to prescribe or use a particular drug or service, or use of medical equipment.
The HHS foots part of the bills for these patients, and it believes that free offerings are kickbacks intended to steer patients to services and drugs they otherwise may not use. If the HHS concludes that kickbacks were at play, it considers any related bills or “claims” to be false claims and a violation.
THIS IS MEMBERS-ONLY CONTENT. To continue reading, choose one of the options below.
News and analysis for the well-informed compliance or audit exec. Select an option and click continue.
Annual Membership $499 Value offer
Full price one year membership with auto-renewal.
Membership $599
One-year only, no auto-renewal.
Admera Health agreed to pay more than $5.5 million to resolve allegations first brought by two whistleblowers that it paid kickbacks to third-party contractors, the Department of Justice said.
New Jersey-based Silver Lake Hospital agreed to pay more than $18.6 million as part of a settlement with the Department of Justice addressing allegations of false claims submitted to Medicare for inpatient cost outlier payments.
Drug manufacturer Akorn Operating Company agreed to pay $7.9 million in a settlement with the Department of Justice for continuing to sell three drugs through Medicare when they were no longer covered under the program.
USAA Federal Savings Bank has been hit with its third cease and desist order from the Treasury Department’s Office of the Comptroller of the Currency in the past five years for failing to correct unsafe and unsound banking practices.
Becton Dickinson medical device company will pay $175 million for “repeatedly” misleading investors about its Alaris infusion pump, a product the company knew was flawed and was sold without the required patient-safety approvals, the Securities and Exchange Commission said.
The Securities and Exchange Commission charged bankrupt fashion retailer Express with failing to disclose nearly $1 million in perks to a former chief executive, but did not levy a financial penalty thanks to its cooperation, the SEC said.
